Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01653912Phase 1Completed

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Role: lead

NCT01507194Phase 2Completed

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

Role: lead

NCT00881946Phase 1Completed

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Role: lead

NCT01424280Phase 1Completed

Single Dose Study of GSK1440115 in Patients With Asthma

Role: lead

NCT01290133Phase 1Completed

Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)

Role: lead

NCT01202214Phase 1Completed

Repeat Dose Safety Study for Compound to Treat Asthma

Role: lead

NCT01186068Phase 2Completed

Dose Response Study of Patients With Erythematous Rosacea

Role: collaborator

All 7 trials loaded